Literature DB >> 31523358

Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.

Aryan Rafiee Zadeh1, Keyvan Ghadimi1, Akram Ataei2, Mozhde Askari1, Neda Sheikhinia2, Nooshin Tavoosi3, Masih Falahatian1.   

Abstract

Multiple Sclerosis (MS) is an autoimmune, inflammatory disease of the central nervous system (CNS) mostly affecting young adults. The exact mechanism and pathogenesis of MS remain still undiscovered but there have been useful treatments with different efficacy rates. Most of these therapies are divided into the first line, second line and third line, impact on the immune system and immune cells. These drugs are approved to be useful in MS, but like any other therapies, adverse effects (AE) are associated with these drugs. In this review, we continue the survey over mechanisms of actions and AEs of MS drugs. Physicians must be aware of such AEs and complications to choose the best drug for each patient.

Entities:  

Keywords:  Mechanism; adverse effect; drug; multiple sclerosis

Year:  2019        PMID: 31523358      PMCID: PMC6737425     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  65 in total

1.  Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.

Authors:  J J Hoefnagel; H B Thio; R Willemze; J N Bouwes Bavinck
Journal:  Br J Dermatol       Date:  2003-08       Impact factor: 9.302

2.  [Treatment of psoriasis vulgaris].

Authors:  W SCHWECKENDIEK
Journal:  Med Monatsschr       Date:  1959-02

3.  Relapse of Graves' disease after successful allogeneic bone marrow transplantation.

Authors:  L T Hsiao; J H Liu; C C Yen; W S Wang; F S Fan; T J Chiou; P M Chen
Journal:  Bone Marrow Transplant       Date:  2001-12       Impact factor: 5.483

4.  Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators.

Authors:  J H Noseworthy; J S Wolinsky; F D Lublin; J N Whitaker; A Linde; P Gjorstrup; H C Sullivan
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

5.  Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

Authors:  C Polman; F Barkhof; M Sandberg-Wollheim; A Linde; O Nordle; T Nederman
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

6.  Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.

Authors:  A J Coles; M Wing; S Smith; F Coraddu; S Greer; C Taylor; A Weetman; G Hale; V K Chatterjee; H Waldmann; A Compston
Journal:  Lancet       Date:  1999-11-13       Impact factor: 79.321

7.  Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.

Authors:  J Goebel; E Stevens; K Forrest; T L Roszman
Journal:  Transpl Immunol       Date:  2000-11       Impact factor: 1.708

8.  Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.

Authors:  G P Rice; M Filippi; G Comi
Journal:  Neurology       Date:  2000-03-14       Impact factor: 9.910

9.  [Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1 (Glatiramer acetate)].

Authors:  C Gaudez; S Regnier; S Aractingi; O Heinzlef
Journal:  Rev Neurol (Paris)       Date:  2003-05       Impact factor: 2.607

Review 10.  From the bench to the bedside: ways to improve rituximab efficacy.

Authors:  Guillaume Cartron; Hervé Watier; Josée Golay; Philippe Solal-Celigny
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

View more
  19 in total

1.  Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Authors:  Saeid Sadeghi Joni; Masoumeh Cheshmavar; Pouria Shoureshi; Zohreh Zamani; Niusha Taoosi; Morteza Akbari; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-06-15

2.  Evaluation of patterns, cause and risk factors of burns in patients with seizure.

Authors:  Seyyed Mahdi Zia Ziabari; Mohammad Reza Mobayen; Sheyda Rimaz; Daniel Rahimi Nejat; Siamak Rimaz
Journal:  Int J Burns Trauma       Date:  2022-02-15

3.  Evaluation of the serum level of osteoprotegerin and bone mineral density in postmenopausal women.

Authors:  Hossein Abdollahi Veshnavei
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-02-15

4.  Platelet-rich plasma therapy or arthroscopic surgery on repair of anterior cruciate ligament rupture.

Authors:  Sepehr Eslami; Shamim Fattah; Soosan Alimohammadzade Taher; Zahra Rezasoltani
Journal:  Eur J Transl Myol       Date:  2022-08-01

5.  Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database.

Authors:  Jodie Belinda Hillen; Ty Stanford; Michael Ward; E E Roughead; Lisa Kalisch Ellett; Nicole Pratt
Journal:  Drugs Real World Outcomes       Date:  2022-08-06

6.  Contrast-enhanced weighted-T1 and FLAIR sequences in MRI of meningeal lesions.

Authors:  Saeid Roozpeykar; Maryam Azizian; Zohreh Zamani; Marjan Rahimi Farzan; Hossein Abdollahi Veshnavei; Nooshin Tavoosi; Arash Toghyani; Amirhossein Sadeghian; Mahdieh Afzali
Journal:  Am J Nucl Med Mol Imaging       Date:  2022-04-15

Review 7.  Alcohol and multiple sclerosis: an immune system-based review.

Authors:  Maryam Fahim; Aryan Rafiee Zadeh; Pouria Shoureshi; Keyvan Ghadimi; Masoumeh Cheshmavar; Neda Sheikhinia; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-04-15

8.  Toll-like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain.

Authors:  Andrew J Kwilasz; Suzanne M Green Fulgham; Julissa Chante Duran-Malle; Anouk E W Schrama; Eric H Mitten; Laurel S Todd; Hardik P Patel; Tracey A Larson; Madison A Clements; Kevin M Harris; Scott T Litwiler; Lewis O Harvey; Steven F Maier; Raymond A Chavez; Kenner C Rice; Anne-Marie Van Dam; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2021-01-07       Impact factor: 7.217

9.  The relationship between menstrual disorders and education in women with intractable epilepsy.

Authors:  Mahdieh Afzali; Jafar Mehvari Habibabadi; Banafsheh Mohammadi; Sanaz Masoumi; Mahta Ranjbar; Masoumeh Cheshmavar; Seyed Navid Naghibi
Journal:  Am J Neurodegener Dis       Date:  2021-12-15

10.  Eating Pattern and Nutritional Risks among People with Multiple Sclerosis Following a Modified Paleolithic Diet.

Authors:  Tyler J Titcomb; Babita Bisht; David D Moore; Yashpal S Chhonker; Daryl J Murry; Linda G Snetselaar; Terry L Wahls
Journal:  Nutrients       Date:  2020-06-20       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.